These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 30689630)

  • 1. Triple oral beta-lactam containing therapy for Buruli ulcer treatment shortening.
    Arenaz-Callao MP; González Del Río R; Lucía Quintana A; Thompson CJ; Mendoza-Losana A; Ramón-García S
    PLoS Negl Trop Dis; 2019 Jan; 13(1):e0007126. PubMed ID: 30689630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of 8 weeks standard treatment (rifampicin plus clarithromycin) vs. 4 weeks standard plus amoxicillin/clavulanate treatment [RC8 vs. RCA4] to shorten Buruli ulcer disease therapy (the BLMs4BU trial): study protocol for a randomized controlled multi-centre trial in Benin.
    Johnson RC; Sáez-López E; Anagonou ES; Kpoton GG; Ayelo AG; Gnimavo RS; Mignanwande FZ; Houezo JG; Sopoh GE; Addo J; Orford L; Vlasakakis G; Biswas N; Calderon F; Della Pasqua O; Gine-March A; Herrador Z; Mendoza-Losana A; Díez G; Cruz I; Ramón-García S
    Trials; 2022 Jul; 23(1):559. PubMed ID: 35804454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amoxicillin/clavulanate in combination with rifampicin/clarithromycin is bactericidal against Mycobacterium ulcerans.
    Sáez-López E; Millán-Placer AC; Lucía A; Ramón-García S
    PLoS Negl Trop Dis; 2024 Apr; 18(4):e0011867. PubMed ID: 38573915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Shortening Buruli Ulcer Treatment with Combination Therapy Targeting the Respiratory Chain and Exploiting Mycobacterium ulcerans Gene Decay.
    Converse PJ; Almeida DV; Tyagi S; Xu J; Nuermberger EL
    Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31036687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-Dose Rifamycins Enable Shorter Oral Treatment in a Murine Model of Mycobacterium ulcerans Disease.
    Omansen TF; Almeida D; Converse PJ; Li SY; Lee J; Stienstra Y; van der Werf T; Grosset JH; Nuermberger EL
    Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30455239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antimicrobial treatment for early, limited Mycobacterium ulcerans infection: a randomised controlled trial.
    Nienhuis WA; Stienstra Y; Thompson WA; Awuah PC; Abass KM; Tuah W; Awua-Boateng NY; Ampadu EO; Siegmund V; Schouten JP; Adjei O; Bretzel G; van der Werf TS
    Lancet; 2010 Feb; 375(9715):664-72. PubMed ID: 20137805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In Vitro Activity of β-Lactams in Combination with β-Lactamase Inhibitors against Multidrug-Resistant Mycobacterium tuberculosis Isolates.
    Zhang D; Wang Y; Lu J; Pang Y
    Antimicrob Agents Chemother; 2016 Jan; 60(1):393-9. PubMed ID: 26525785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paradoxical Hypersusceptibility of Drug-resistant Mycobacteriumtuberculosis to β-lactam Antibiotics.
    Cohen KA; El-Hay T; Wyres KL; Weissbrod O; Munsamy V; Yanover C; Aharonov R; Shaham O; Conway TC; Goldschmidt Y; Bishai WR; Pym AS
    EBioMedicine; 2016 Jul; 9():170-179. PubMed ID: 27333036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of rifampicin-streptomycin for treatment of Buruli ulcer: a systematic review.
    Tanywe A; Fernandez RS
    JBI Database System Rev Implement Rep; 2017 Jan; 15(1):119-139. PubMed ID: 28085731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In-vitro activity of avermectins against Mycobacterium ulcerans.
    Omansen TF; Porter JL; Johnson PD; van der Werf TS; Stienstra Y; Stinear TP
    PLoS Negl Trop Dis; 2015 Mar; 9(3):e0003549. PubMed ID: 25742173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of an Acid-Oxidizing Solution against Mycobacterium ulcerans.
    Warryn L; Pluschke G
    Antimicrob Agents Chemother; 2022 Jan; 66(1):e0087021. PubMed ID: 34662181
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selamectin Is the Avermectin with the Best Potential for Buruli Ulcer Treatment.
    Scherr N; Pluschke G; Thompson CJ; Ramón-García S
    PLoS Negl Trop Dis; 2015 Aug; 9(8):e0003996. PubMed ID: 26270480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oxazolidinones Can Replace Clarithromycin in Combination with Rifampin in a Mouse Model of Buruli Ulcer.
    Almeida DV; Omansen TF; Li SY; Lee J; Grosset JH; Converse PJ; Nuermberger EL
    Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30559131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Paradoxical reactions and responses during antibiotic treatment for Mycobacterium ulcerans infection (Buruli ulcer). Four cases from French Guiana].
    Sambourg E; Dufour J; Edouard S; Morris A; Mosnier E; Reynaud Y; Sainte-Marie D; Nacher M; Guégan JF; Couppié P
    Ann Dermatol Venereol; 2014; 141(6-7):413-8. PubMed ID: 24951139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and bacteriological efficacy of rifampin-streptomycin combination for two weeks followed by rifampin and clarithromycin for six weeks for treatment of Mycobacterium ulcerans disease.
    Phillips RO; Sarfo FS; Abass MK; Abotsi J; Wilson T; Forson M; Amoako YA; Thompson W; Asiedu K; Wansbrough-Jones M
    Antimicrob Agents Chemother; 2014; 58(2):1161-6. PubMed ID: 24323473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Compliance with antimicrobial therapy for buruli ulcer.
    Klis S; Kingma R; Tuah W; Stienstra Y; van der Werf TS
    Antimicrob Agents Chemother; 2014 Oct; 58(10):6340. PubMed ID: 25225342
    [No Abstract]   [Full Text] [Related]  

  • 17. Activities of rifampin, Rifapentine and clarithromycin alone and in combination against mycobacterium ulcerans disease in mice.
    Almeida D; Converse PJ; Ahmad Z; Dooley KE; Nuermberger EL; Grosset JH
    PLoS Negl Trop Dis; 2011 Jan; 5(1):e933. PubMed ID: 21245920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reply to "compliance with antimicrobial therapy for buruli ulcer".
    Phillips RO; Sarfo FS; Abass MK; Frimpong M; Ampadu E; Forson M; Amoako YA; Thompson W; Asiedu K; Wansbrough-Jones M
    Antimicrob Agents Chemother; 2014 Oct; 58(10):6341. PubMed ID: 25225343
    [No Abstract]   [Full Text] [Related]  

  • 19. Meropenem-clavulanate has high in vitro activity against multidrug-resistant Mycobacterium tuberculosis.
    Davies Forsman L; Giske CG; Bruchfeld J; Schön T; Juréen P; Ängeby K
    Int J Mycobacteriol; 2015 Mar; 4 Suppl 1():80-1. PubMed ID: 27128620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Buruli Ulcer: Review of a Neglected Skin Mycobacterial Disease.
    Guarner J
    J Clin Microbiol; 2018 Apr; 56(4):. PubMed ID: 29343539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.